Boundless Bio Stock

boundlessbio.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $756.15MM

Boundless Bio, founded in 2018, is a biopharmaceutical company that develops novel cancer therapeutics seeking to understand and treat intractable cancers. Boundless Bio aims to interrogate extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers. Boundless Bio is headquartered in La Jolla, California.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Boundless Bio before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Boundless Bio Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Boundless Bio Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
05/16/2023 Series C $100MM $xx.xx $273.76MM Bayer, Healthcare Capital, Piper Heartland, Ra Capital Management, Sectoral Asset Management
Price per Share
$xx.xx
Shares Outstanding
142,857,138
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bayer, Healthcare Capital, Piper Heartland, Ra Capital Management, Sectoral Asset Management
04/28/2021 Series B $105.59MM $xx.xx $262.52MM Alexandria Venture Investments, Arch Venture Partners, Boxer Capital, City Hill Ventures, Fidelity, Gt Healthcare Capital Partners, Logos Capital, Nextech, Pfm Health Sciences, Ra Capital Management, Redmile Group, Surveyor Capital, Vertex Ventures Hc, Wellington Management
Price per Share
$xx.xx
Shares Outstanding
78,211,116
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Arch Venture Partners, Boxer Capital, City Hill Ventures, Fidelity, Gt Healthcare Capital Partners, Logos Capital, Nextech, Pfm Health Sciences, Ra Capital Management, Redmile Group, Surveyor Capital, Vertex Ventures Hc, Wellington Management
09/19/2019 Series A $46.47MM $xx.xx $103.26MM Alexandria Venture Investments, Arch Venture Partners, Boxer Capital, City Hill Ventures, Gt Healthcare Capital Partners, Vertex Ventures
Price per Share
$xx.xx
Shares Outstanding
66,378,590
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Arch Venture Partners, Boxer Capital, City Hill Ventures, Gt Healthcare Capital Partners, Vertex Ventures

Boundless Bio Investors Also Invested in These Private Companies

Cambridge Innovation Capital
Sectoral Asset Management
National Cancer Institute
City Hill Ventures
Tavistock Group
GT Healthcare Capital Partners
Citadel Enterprise Americas

Leadership & Board

Leadership

Zachary Hornby
Chief Executive Officer & President
Christian Hassig Ph.D
Chief Scientific Officer
Neil Abdollahian
Chief Business Officer
Jonathan Lim MD
Co-Founder
Benjamin Cravatt Ph.D
Co-Founder
Klaus Wagner Ph.D
Chief Medical Officer

Board

Christine Brennan Ph.D
Vertex Ventures HC
Fabio Pucci Ph.D
RA Capital Management
Kristina Burow
ARCH Venture Partners

Boundless Bio stock FAQs

plusminus

Can you buy Boundless Bio stock?

You can no longer buy Boundless Bio stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Boundless Bio stock?

You can no longer buy Boundless Bio stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Boundless Bio stock?

You can no longer sell stock of Boundless Bio on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Boundless Bio stock?

You can no longer sell stock of Boundless Bio on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is Boundless Bio a public company?

Boundless Bio is now a public company traded on NASDAQ with ticker BOLD.
plusminus

What is Boundless Bio’s stock price?

The stock price of Boundless Bio is not currently available.
plusminus

What is Boundless Bio’s stock ticker symbol?

The ticker symbol of Boundless Bio is BOLD.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Boundless Bio News and Media Highlights

Boundless ups fundraising by Leaps and bounds, adding another $100M haul

Boundless Bio, the precision oncology company working on treatments for oncogene-amplified cancers, is amping up its fundraising with a new $100 million series C round backed by Leaps by Bayer and RA Capital Management.

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification

Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancer, today announced that the first patient has been dosed with BBI-355 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic solid tumors with oncogene amplifications (NCT05827614).
Browse Insights
Updated on: Dec 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.